Hypertension in diabetes patients overtreated?

Australian and international investigators in the ADVANCE trial found in a post hoc analysis that not all patients gain equivalent benefit from BP-lowering treatment and that an algorithm based on routine clinical data could identify patients with T2DM who would benefit most from the drugs.

Sole reliance on BP levels to guide treatment initiation suggested that risk “suddenly increases” when BP reaches a specific cut-off, the researchers led by Professor John Chalmers from the George Institute in
Sydney said.

“There’s an automatic tend­ency in doctors’ minds that once people hit 140/90mmHg we’ve got to get out our prescription pad,” agreed Professor Mark Harris, a leading primary care researcher, who was not involved in the study.
ADVANCE was a randomised controlled trial evaluating the effect of intensive glucose control and routine BP-lowering therapy